NOVEMBER 9, 2017
This October, Phyton Biotech attended CPhI Worldwide to exhibit its capabilities and the wide range of applications for the company’s proprietary Plant Cell Fermentation Technology (PCF®).
CPhI Worldwide is the largest pharmaceutical industry trade show, bringing together pharmaceutical industry suppliers and buyers from all over the world. This year, the conference was held in Frankfurt over three days in late October.
Phyton Biotech has participated in the conference for over eight years, and this year, we put significant effort into showcasing our capabilities on PCF® and its broad application to pharmaceuticals and traditional Chinese medicines. The company’s Chief Scientific Officer, Dr. Gilbert Gorr, presented on the topic of “Applications of Plant Cell Cultures – from bench to commercial scale” to a large audience at the Pharma Insight Briefing. Dr. Gorr shared several case studies of compounds that Phyton Biotech has developed via PCF® and discussed how the best performing cell lines are selected. He also discussed how the percentage content of an active compound is improved using PCF® versus from the natural plant source. View his presentation.
The Phyton Biotech booth was a hub of activity with visitors ranging from buyers of our key commercial products derived from PCF® – paclitaxel and docetaxel API – and visitors inquiring about how they could benefit from the application of PCF® to develop their unique, complex plant-based compounds, which are difficult to extract from natural plants. Phyton Biotech’s business development team was extremely busy over the course of the conference, meeting with 40 current and potential clients and buyers.
Next year, CPhI will be held in Madrid in October. Phyton Biotech’s business development team will be there again to introduce new products and PCF® technology projects, undoubtedly piquing the interest of potential customers who would like to see innovation fermenting.